ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9732
-0.06%
Brent Oil
83.23
0.13%
Bitcoin
64,253.92
0.40%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Entrada Therapeutics Inc (TRDA)

  7. Entrada Therapeutics Inc (TRDA) Noticias

TRDA Entrada Therapeutics Inc

13.16
-0.40 (-2.95%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Entrada Therapeutics Inc TRDA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.40 -2.95% 13.16 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
13.70 12.92 13.91 13.16 13.56
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/3/202406:00GLOBEEntrada Therapeutics Reports Fourth Quarter and Full Year..
08/3/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202415:22EDGAR2Form 144 - Report of proposed sale of securities
06/3/202415:22EDGAR2Form 144 - Report of proposed sale of securities
05/3/202418:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202406:00GLOBEEntrada Therapeutics to Present at Upcoming Investor..
03/1/202406:16EDGAR2Form 8-K - Current report
03/1/202406:00GLOBEEntrada Therapeutics Promotes Nathan J. Dowden to President
26/12/202315:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202315:26EDGAR2Form 144 - Report of proposed sale of securities
06/12/202306:00EDGAR2Form 8-K - Current report
22/11/202310:56DJNEntrada Therapeutics Shares Tumble 27% After FDA Keeps..
22/11/202306:54DJNEntrada: FDA Declines to Lift Hold on Duchenne Study
22/11/202306:35EDGAR2Form 8-K - Current report
22/11/202306:00GLOBEEntrada Therapeutics Announces Updates on ENTR-601-44 in..
07/11/202306:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:08EDGAR2Form 8-K - Current report
07/11/202306:00GLOBEEntrada Therapeutics Reports Third Quarter 2023 Financial..
01/11/202306:01EDGAR2Form 8-K - Current report
12/10/202306:00GLOBEEntrada Therapeutics to Present at Upcoming Investor..
29/9/202315:39EDGAR2Form 8-K - Current report
29/9/202315:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/9/202306:09EDGAR2Form 8-K - Current report
21/9/202306:00GLOBEEntrada Therapeutics Announces First Participant Dosed in..
07/9/202306:00GLOBEEntrada Therapeutics Awards Funding to Non-Profit..
06/9/202316:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202316:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202316:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202316:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202315:09EDGAR2Form 144 - Report of proposed sale of securities
06/9/202315:09EDGAR2Form 144 - Report of proposed sale of securities
06/9/202315:08EDGAR2Form 144 - Report of proposed sale of securities
05/9/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/8/202306:00GLOBEEntrada Therapeutics to Present at Upcoming Investor..
10/8/202306:09EDGAR2Form 8-K - Current report
10/8/202306:00GLOBEEntrada Therapeutics Appoints Gina Chapman to its Board of..
08/8/202306:25EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
08/8/202306:23EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
08/8/202306:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:07EDGAR2Form 8-K - Current report
08/8/202306:00GLOBEEntrada Therapeutics Reports Second Quarter 2023 Financial..
04/8/202315:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202315:10EDGAR2Form 144 - Report of proposed sale of securities
01/8/202306:08EDGAR2Form 8-K - Current report
01/8/202306:00GLOBEEntrada Therapeutics Receives Authorization in the United..
12/7/202315:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
TRDA
Entrada Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados